AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice
Open Access
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 15, 194-203
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (2R01HD052682-06A1)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K01AR066077)
This publication has 53 references indexed in Scilit:
- Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe MiceJournal of Biological Chemistry, 2013
- Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman PrimatesHuman Gene Therapy, 2012
- Facial‐muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapyJournal of Inherited Metabolic Disease, 2011
- Expanding the phenotype of late‐onset pompe disease: Tongue weakness: A new clinical observationMuscle & Nerve, 2011
- Pompe disease gene therapyHuman Molecular Genetics, 2011
- Hypoglossal Neuropathology and Respiratory Activity in Pompe MiceFrontiers in Physiology, 2011
- Gel-mediated Delivery of AAV1 Vectors Corrects Ventilatory Function in Pompe Mice With Established DiseaseMolecular Therapy, 2010
- Neural deficits contribute to respiratory insufficiency in Pompe diseaseProceedings of the National Academy of Sciences, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe diseaseMolecular Genetics and Metabolism, 2008